9 Meters Biopharma Inc. (NASDAQ:NMTR) went up by 3.70% from its latest closing price compared to the recent 1-year high of $2.26. The company’s stock price has collected -0.88% of loss in the last five trading sessions. Press Release reported on 07/19/21 that 9 Meters Biopharma, Inc. Announces the Acquisition of Humanized Anti-GIP Monoclonal Antibody from Lobesity
Is It Worth Investing in 9 Meters Biopharma Inc. (NASDAQ :NMTR) Right Now?
Plus, the 36-month beta value for NMTR is at -3.93. Opinions of the stock are interesting as 7 analysts out of 7 who provided ratings for 9 Meters Biopharma Inc. declared the stock was a “buy,” while 0 rated the stock as “overweight,” 0 rated it as “hold,” and 0 as “sell.”
The average price from analysts is $4.58. NMTR currently public float of 180.50M and currently shorts hold a 5.11% ratio of that float. Today, the average trading volume of NMTR was 5.05M shares.
NMTR’s Market Performance
NMTR stocks went down by -0.88% for the week, with a monthly drop of -16.42% and a quarterly performance of 7.69%, while its annual performance rate touched 103.64%. The volatility ratio for the week stands at 6.52% while the volatility levels for the past 30 days are set at 8.42% for 9 Meters Biopharma Inc.. The simple moving average for the period of the last 20 days is -4.15% for NMTR stocks with a simple moving average of -5.80% for the last 200 days.
Analysts’ Opinion of NMTR
Many brokerage firms have already submitted their reports for NMTR stocks, with BMO Capital Markets repeating the rating for NMTR by listing it as a “Outperform.” The predicted price for NMTR in the upcoming period, according to BMO Capital Markets is $5 based on the research report published on July 08th of the current year 2021.
Citigroup, on the other hand, stated in their research note that they expect to see NMTR reach a price target of $3. The rating they have provided for NMTR stocks is “Buy” according to the report published on June 04th, 2021.
NMTR Trading at -9.19% from the 50-Day Moving Average
After a stumble in the market that brought NMTR to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -50.44% of loss for the given period.
Volatility was left at 8.42%, however, over the last 30 days, the volatility rate increased by 6.52%, as shares sank -20.00% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -4.27% lower at present.
During the last 5 trading sessions, NMTR fell by -0.88%, which changed the moving average for the period of 200-days by +35.43% in comparison to the 20-day moving average, which settled at $1.1545. In addition, 9 Meters Biopharma Inc. saw 30.38% in overturn over a single year, with a tendency to cut further gains.
Reports are indicating that there were more than several insider trading activities at NMTR starting from OrbiMed Israel GP Ltd., who sale 15,989,876 shares at the price of $1.21 back on Jun 25. After this action, OrbiMed Israel GP Ltd. now owns 8,565,974 shares of 9 Meters Biopharma Inc., valued at $19,347,750 using the latest closing price.
OrbiMed Israel GP Ltd., the 10% Owner of 9 Meters Biopharma Inc., sale 319,255 shares at $1.38 during a trade that took place back on Jun 24, which means that OrbiMed Israel GP Ltd. is holding 24,555,850 shares at $440,572 based on the most recent closing price.
Stock Fundamentals for NMTR
The total capital return value is set at -165.11, while invested capital returns managed to touch -541.91. Equity return is now at value -347.50, with -234.60 for asset returns.
Based on 9 Meters Biopharma Inc. (NMTR), the company’s capital structure generated 0.72 points at debt to equity in total, while total debt to capital is 0.71. Total debt to assets is 0.59, with long-term debt to equity ratio resting at 0.52. Finally, the long-term debt to capital ratio is 0.52.
The liquidity ratio also appears to be rather interesting for investors as it stands at 5.68.